<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Ocular</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>LHON updates: Gene therapy progress; idebenone receives US CRL </title>
      <description>
        <![CDATA[Chiesi Group’s idebenone faced a regulatory setback last month after the U.S. FDA issued a complete response letter (CRL) to the company’s NDA for Leber hereditary optic neuropathy (LHON), a rare inherited disorder that causes sudden vision loss.But a chance missed for Chiesi may be an opportunity for gene therapies, including Gensight Biologics SA’s lenadogene nolparvovec (Lumevoq; GS-010).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730074</guid>
      <pubDate>Thu, 02 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730074-lhon-updates-gene-therapy-progress-idebenone-receives-us-crl</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eya-and-DNA-illustration.webp?t=1658513444" type="image/png" medium="image" fileSize="350713">
        <media:title type="plain">Eye and DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730089</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730089-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Highly complementary Biogen pays $5.6B; who’s jealous of Apellis? </title>
      <description>
        <![CDATA[Biogen Inc. hardly blinked at the competition faced by Apellis Pharmaceuticals Inc. as the two companies sealed a deal whereby the former has agreed to acquire all outstanding shares of the latter for $41 each, or about $5.6 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729963</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729963-highly-complementary-biogen-pays-56b-whos-jealous-of-apellis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake-with-charts-maps-data.webp?t=1701801114" type="image/jpeg" medium="image" fileSize="281005">
        <media:title type="plain">Handshake with charts, maps, data</media:title>
      </media:content>
    </item>
    <item>
      <title>Elegrobart star in TED phase III but Viridian shares sacked</title>
      <description>
        <![CDATA[Analysts were sounding pleased and the company intends to go ahead with a regulatory filing, but investors seem to have wanted more from Viridian Therapeutics Inc.’s top-line data from the elegrobart (formerly VRDN-003) Reveal-1 phase III trial in active thyroid eye disease (TED). Viridian shares (NASDAQ:VRDN) closed March 30 at $18.53, down $8.86, or 32%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729946</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729946-elegrobart-star-in-ted-phase-iii-but-viridian-shares-sacked</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-eye1.webp?t=1589292057" type="image/png" medium="image" fileSize="296406">
        <media:title type="plain">Face with digital focus on eye</media:title>
      </media:content>
    </item>
    <item>
      <title>Kodiak’s Zenkuda sparkles in Glow2, BLA filing next</title>
      <description>
        <![CDATA[After previous setbacks with the program, investors largely brushed aside ocular-focused Kodiak Sciences Inc.’s anticipated phase III Glow2 data of tarcocimab tedromer in diabetic retinopathy (DR), so the positive top-line superiority results revealed March 26 caught many by surprise as it sets the company up for an accelerated multi-indication BLA submission.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729899</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729899-kodiaks-zenkuda-sparkles-in-glow2-bla-filing-next</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-wireframe-illustration.webp?t=1688152353" type="image/jpeg" medium="image" fileSize="165854">
        <media:title type="plain">Eye wireframe illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729841</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729841-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Aldeyra collects third CRL for reproxalap in dry eye disease</title>
      <description>
        <![CDATA[It’s déjà vu all over again for Aldeyra Therapeutics Inc., which disclosed its third complete response letter (CRL) for dry eye disease candidate reproxalap, with the U.S. FDA citing a lack of substantial and consistent evidence of efficacy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729718</guid>
      <pubDate>Tue, 17 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729718-aldeyra-collects-third-crl-for-reproxalap-in-dry-eye-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-eye-analysis.webp?t=1682529922" type="image/png" medium="image" fileSize="566355">
        <media:title type="plain">Close up of man's eye</media:title>
      </media:content>
    </item>
    <item>
      <title>P2X7 receptor antagonists detailed in Breye Therapeutics patent</title>
      <description>
        <![CDATA[Breye Therapeutics Aps has reported P2X purinoceptor 7 (P2RX7; P2X7) antagonists potentially useful for the treatment of age-related macular degeneration (AMD), cardiovascular, cognitive, eating disorder, headache, liver diseases, neurodegeneration and neuroinflammation, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729683</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729683-p2x7-receptor-antagonists-detailed-in-breye-therapeutics-patent</link>
    </item>
    <item>
      <title>Resident macrophages reveal the immune side of glaucoma</title>
      <description>
        <![CDATA[Scientists at Duke University have uncovered how macrophages help maintain intraocular pressure and have found that a specific type, resident macrophages, is essential for proper drainage of intraocular fluid. When these cells are removed, drainage becomes impaired and intraocular pressure rises, contributing to the development of glaucoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729662</guid>
      <pubDate>Thu, 12 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729662-resident-macrophages-reveal-the-immune-side-of-glaucoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Aqueous-humor-drainage-from-the-eye.webp?t=1773240930" type="image/jpeg" medium="image" fileSize="611343">
        <media:title type="plain">Illustration showing aqueous humor drainage from the eye</media:title>
        <media:description type="plain">Aqueous humor drainage from the eye regulates intraocular pressure. It passes through the trabeculum and Schlemm’s canal, preventing glaucoma.</media:description>
      </media:content>
    </item>
    <item>
      <title>Three pediatric brain cancer types share a pineal gland origin</title>
      <description>
        <![CDATA[Similarities among three pediatric brain tumors that arise in different structures of the CNS – pineoblastoma, retinoblastoma and Group 3 medulloblastoma – have been linked to their shared origin during pineal gland development. Scientists at St. Jude Children’s Research Hospital have identified the molecular signatures that drive these tumors from pinealocyte progenitor cells that conserve a common differentiation program, providing a shared therapeutic target for these three cancer types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729642</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729642-three-pediatric-brain-cancer-types-share-a-pineal-gland-origin</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-Pineal-gland.webp?t=1773154224" type="image/jpeg" medium="image" fileSize="214692">
        <media:title type="plain">Illustration of brain cross-section showing the pineal gland</media:title>
      </media:content>
    </item>
    <item>
      <title>Resident macrophages reveal the immune side of glaucoma</title>
      <description>
        <![CDATA[Scientists at Duke University have uncovered how macrophages help maintain intraocular pressure and have found that a specific type, resident macrophages, is essential for proper drainage of intraocular fluid. When these cells are removed, drainage becomes impaired and intraocular pressure rises, contributing to the development of glaucoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729587</guid>
      <pubDate>Wed, 11 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729587-resident-macrophages-reveal-the-immune-side-of-glaucoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Aqueous-humor-drainage-from-the-eye.webp?t=1773240930" type="image/jpeg" medium="image" fileSize="611343">
        <media:title type="plain">Illustration showing aqueous humor drainage from the eye</media:title>
        <media:description type="plain">Aqueous humor drainage from the eye regulates intraocular pressure. It passes through the trabeculum and Schlemm’s canal, preventing glaucoma.</media:description>
      </media:content>
    </item>
    <item>
      <title>Roche identifies new soluble epoxide hydrolase inhibitors</title>
      <description>
        <![CDATA[F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized pyridone carboxamide-derived compounds acting as soluble epoxide hydrolase inhibitors. They are reported to be useful for the treatment of diabetic retinopathy, neuropathic pain and neurodegenerative diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729522</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729522-roche-identifies-new-soluble-epoxide-hydrolase-inhibitors</link>
    </item>
    <item>
      <title>Three pediatric brain cancer types share a pineal gland origin</title>
      <description>
        <![CDATA[Similarities among three pediatric brain tumors that arise in different structures of the CNS – pineoblastoma, retinoblastoma and Group 3 medulloblastoma – have been linked to their shared origin during pineal gland development. Scientists at St. Jude Children’s Research Hospital have identified the molecular signatures that drive these tumors from pinealocyte progenitor cells that conserve a common differentiation program, providing a shared therapeutic target for these three cancer types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729507</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729507-three-pediatric-brain-cancer-types-share-a-pineal-gland-origin</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-Pineal-gland.webp?t=1773154224" type="image/jpeg" medium="image" fileSize="214692">
        <media:title type="plain">Illustration of brain cross-section showing the pineal gland</media:title>
      </media:content>
    </item>
    <item>
      <title>EB-203 improves diabetic retinopathy-like pathology in zebrafish</title>
      <description>
        <![CDATA[In a recent publication in <em>Biomedicine & Pharmacotherapy</em>, investigators evaluated the activity of a 7-amino-acid peptide, EB-203, using a zebrafish model of diabetic retinopathy (DR)-like vascular alterations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729419</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729419-eb-203-improves-diabetic-retinopathy-like-pathology-in-zebrafish</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-eye-diabetic-retinopathy-illustration.webp?t=1773070137" type="image/jpeg" medium="image" fileSize="149131">
        <media:title type="plain">Illustration showing cross section of eye with diabetic retinopathy</media:title>
      </media:content>
    </item>
    <item>
      <title>GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D</title>
      <description>
        <![CDATA[Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729391</guid>
      <pubDate>Fri, 06 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729391-gwas-identifies-variant-associated-with-diabetic-retinopathy-and-susceptibility-to-t2d</link>
    </item>
    <item>
      <title>Sanaregen Vision’s SVT-001 cleared for clinic for familial drusen</title>
      <description>
        <![CDATA[Sanaregen Vision Therapeutics Inc. has received FDA clearance to conduct a phase I/II trial of SVT-001, an investigational cell therapy for individuals with familial drusen.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729151</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729151-sanaregen-visions-svt-001-cleared-for-clinic-for-familial-drusen</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-macula-diagram.webp?t=1713453488" type="image/jpeg" medium="image" fileSize="294587">
        <media:title type="plain">Medical vector illustration showing cross section of an eyeball with close up of the macula</media:title>
      </media:content>
    </item>
    <item>
      <title>New mouse model of Sjögren’s disease-associated dry eye</title>
      <description>
        <![CDATA[Scientists based at Capital Medical University (Beijing, China) have designed a lacrimal gland-specific autoimmune model that recapitulates the main features of Sjögren’s disease-associated dry eye.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728970</guid>
      <pubDate>Mon, 23 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728970-new-mouse-model-of-sjogrens-disease-associated-dry-eye</link>
    </item>
    <item>
      <title>Subretinal NRF2 gene therapy preserves retinal function in dry AMD models</title>
      <description>
        <![CDATA[Researchers from Harvard Medical School and Spark Therapeutics Inc. tested subretinal NRF2 gene therapy in dry AMD models to investigate whether it could relieve oxidative stress and inflammation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728955</guid>
      <pubDate>Fri, 20 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728955-subretinal-nrf2-gene-therapy-preserves-retinal-function-in-dry-amd-models</link>
    </item>
    <item>
      <title>Financing at Gelmedix supports GMX-101 for geographic atrophy</title>
      <description>
        <![CDATA[Gelmedix Inc. has completed a $13 million seed financing to support progression of the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage geographic atrophy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728920</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728920-financing-at-gelmedix-supports-gmx-101-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RD-money.webp?t=1588877677" type="image/png" medium="image" fileSize="578436">
        <media:title type="plain">Dollar sign droplet above test tube</media:title>
      </media:content>
    </item>
    <item>
      <title>Eylea threatened Inlyta Ocular’s phase III win with Axpaxli?</title>
      <description>
        <![CDATA[Ocular Therapeutix Inc.’s wet age-macular degeneration candidate, Axpaxli, beat anti-VEGF therapy Eylea (aflibercept) from Regeneron Pharmaceuticals Inc. in the phase III head-to-head trial called Sol-1, but not by enough of a margin for Wall Street. Shares of the firm (NASDAQ:OCUL) closed Feb. 17 at $6.99, down $1.89, or 21%, as investors mulled the top-line findings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728992</guid>
      <pubDate>Tue, 17 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728992-eylea-threatened-inlyta-oculars-phase-iii-win-with-axpaxli</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/eye-analysis.webp?t=1589292229" type="image/png" medium="image" fileSize="545833">
        <media:title type="plain">Close-up of eye with digital focus</media:title>
      </media:content>
    </item>
    <item>
      <title>CaMKII gene therapy is protective in models of eye disorders</title>
      <description>
        <![CDATA[A recent study published in <em>Molecular Therapy</em> by researchers from West China Hospital at Sichuan University and collaborators aimed to investigate the effect of CaMKII gene therapy on retinal ganglion cell (RGC) protection in mouse models of retinal ischemia/reperfusion (I/R) injury and congenital glaucoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728884</guid>
      <pubDate>Mon, 16 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728884-camkii-gene-therapy-is-protective-in-models-of-eye-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/eye-retina.webp?t=1721143096" type="image/jpeg" medium="image" fileSize="224529">
        <media:title type="plain">Illustration of human eye </media:title>
      </media:content>
    </item>
    <item>
      <title>New models, gene therapy approach for ocular phenotype of Friedreich’s ataxia</title>
      <description>
        <![CDATA[Friedreich’s ataxia (FA), the most common form of hereditary ataxia, is an autosomal recessive neurodegenerative disorder affecting multiple organ systems, and causing cardiomyopathy, scoliosis, muscle weakness, speech impairment and other systemic issues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728817</guid>
      <pubDate>Thu, 12 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728817-new-models-gene-therapy-approach-for-ocular-phenotype-of-friedreichs-ataxia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-genetics.webp?t=1604004459" type="image/png" medium="image" fileSize="576486">
        <media:title type="plain">Optogenetics illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>ALKBH5-ERK1/2 identified as a new therapeutic axis in myopia</title>
      <description>
        <![CDATA[Myopia is a refractive disorder caused by excessive axial elongation, leading to blurred distance vision. Its development involves genetic, environmental and molecular factors, including retinal <em>N</em>6-methyladenosine (m6A) RNA modification.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728743</guid>
      <pubDate>Mon, 09 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728743-alkbh5-erk1-2-identified-as-a-new-therapeutic-axis-in-myopia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Womans-profile-with-eye-chart.webp?t=1770651700" type="image/jpeg" medium="image" fileSize="619549">
        <media:title type="plain">Woman's profile with eye chart</media:title>
      </media:content>
    </item>
    <item>
      <title>More biopharma IPOs: Agomab raises $200M, Spyglass gets $150M</title>
      <description>
        <![CDATA[Another two biopharma companies priced IPOs on Nasdaq to raise a combined $350 million, becoming the fourth and fifth firms to debut on U.S. markets in 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728763</guid>
      <pubDate>Fri, 06 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728763-more-biopharma-ipos-agomab-raises-200m-spyglass-gets-150m</link>
    </item>
    <item>
      <title>Insilico Medicine selects NLRP3 inhibitor preclinical candidate</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco has nominated ISM-5059, a peripherally restricted small-molecule NLRP3 inhibitor, as a preclinical candidate.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728677</guid>
      <pubDate>Fri, 06 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728677-insilico-medicine-selects-nlrp3-inhibitor-preclinical-candidate</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NLRP3-inflammasome.webp?t=1687271826" type="image/jpeg" medium="image" fileSize="295477">
        <media:title type="plain">NLRP3 inflammasome</media:title>
      </media:content>
    </item>
    <item>
      <title>Meiragtx licenses Zipbio’s gene therapies for geographic atrophy</title>
      <description>
        <![CDATA[Zipbio has signed an exclusive license agreement with Meiragtx Holdings plc to advance an AAV gene therapy for geographic atrophy. Under the agreement, Meiragtx will receive exclusive rights to Zipbio’s first-in-class therapies targeting the complement pathway for geographic atrophy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728602</guid>
      <pubDate>Wed, 04 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728602-meiragtx-licenses-zipbios-gene-therapies-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eya-and-DNA-illustration.webp?t=1658513444" type="image/png" medium="image" fileSize="350713">
        <media:title type="plain">Eye and DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Alchemedicine patents CFD inhibitors</title>
      <description>
        <![CDATA[Alchemedicine Inc. has disclosed complement factor D (CFD) inhibitors described as potentially useful for the treatment of age-related macular degeneration, arthritis, Alzheimer’s disease, multiple sclerosis, ulcerative colitis, diabetic retinopathy, glaucoma and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728519</guid>
      <pubDate>Tue, 03 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728519-alchemedicine-patents-cfd-inhibitors</link>
    </item>
    <item>
      <title>Tenpoint advantage? FDA clears presbyopia duo-drop  </title>
      <description>
        <![CDATA[The presbyopia space gained another player as Tenpoint Therapeutics Ltd. won the U.S. FDA’s go-ahead for Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution, 2.75%/0.1%, previously known as Brimochol PF), the first and only dual-agent eye drop for the treatment of adult presbyopia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728475</guid>
      <pubDate>Thu, 29 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728475-tenpoint-advantage-fda-clears-presbyopia-duo-drop</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-drops.webp?t=1589826728" type="image/png" medium="image" fileSize="516734">
        <media:title type="plain">Eye drops</media:title>
      </media:content>
    </item>
    <item>
      <title>Life Biosciences’ ER-100 cleared for clinic in optic neuropathies</title>
      <description>
        <![CDATA[Life Biosciences Inc. has obtained IND clearance from the FDA for ER-100 in optic neuropathies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728416</guid>
      <pubDate>Thu, 29 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728416-life-biosciences-er-100-cleared-for-clinic-in-optic-neuropathies</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/neurology-ocular-optic-nerve-neuropathy.webp?t=1769700970" type="image/jpeg" medium="image" fileSize="428955">
        <media:title type="plain">Illustration of the optic nerve connecting eye to brain</media:title>
      </media:content>
    </item>
    <item>
      <title>Suzhou Raymon Pharmaceuticals synthesizes NO-donor-containing compounds</title>
      <description>
        <![CDATA[Suzhou Raymon Pharmaceuticals Co. Ltd. has identified nitric oxide (NO) donor-containing compounds reported to be useful for the treatment of glaucoma, age-related macular degeneration, diabetic retinopathy, cataract, uveitis, keratitis and ocular hypertension.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728389</guid>
      <pubDate>Tue, 27 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728389-suzhou-raymon-pharmaceuticals-synthesizes-no-donor-containing-compounds</link>
    </item>
  </channel>
</rss>
